GMAB News and Press, Genmab A/S From 02/15/22

Genmab (NASDAQ:GMAB) is scheduled to announce FY earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is $6.50 and the consensus revenue estimate is $1.28B. Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. Revenue estimates h...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Genmab has an impressive pipeline of proprietary and partnered programs in development. In addition, the company has developed or helped develop five FDA-approved monoclonal antibody therapies. The company’s revenue is mostly recurring royalties and milestones through licensing...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November

The PD-1 blocker market has exploded into place as one of the most important and promising major biopharma oncology markets yet to appear. Immuno-oncology drugs that block the checkpoint PD-1 have been some of the most successful stories in the industry over recent years, launching blockbuste...

Genmab A/S (GMAB) Q3 2021 Results Conference Call November 10, 2021 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Conference Call Participants Wimal Kapadia - Bernstein James Gordo...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q3 earnings call. For further details see: Genmab A/S 2021 Q3 - Results - Earnings Call Presentation

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody®-CD3xCD20) in combination with other treatments in patients with B-cell non-Hodgkin lymphoma (NHL) Poster presentation highlighting preliminary data from clinical trial evalua...